Randomized, placebo-controlled trial reveals the impact of dose and timing of Bifidobacterium infantis probiotic supplementation on breastfed infants’ gut microbiome
mSphere · 2026
DOI: 10.1128/msphere.00518-25 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift mSphere, 2026. Verfasst von Claire E O'Brien und 8 weiteren Autor:innen. Beteiligte Einrichtung: Health and Environmental Sciences Institute, Washington, DC, USA. Hauptthemen laut MEDLINE: Probiotics, Gastrointestinal Microbiome, Breast Feeding, Bifidobacterium longum subspecies infantis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A dysfunctional gut microbiome has become increasingly common in infants born in high-income countries as Bifidobacterium strains no longer dominate the gut microbiome. Probiotics containing Bifidobacterium infantis have been used in breastfed newborns to successfully restore the gut microbiome; however, no studies to date have demonstrated this effect in older breastfed infants whose gut microbiomes are transitioning toward stability and maturity. This is a 9-week randomized controlled trial wherein 2–4 months old exclusively breastfed infants ( n = 40) received 0 CFU/day B. infantis EVC001 (placebo), 4.0 × 10 9 CFU/day B. infantis EVC001 (low), 8.0 × 10 9 CFU/day B. infantis EVC001 (medium), or 1.8 × 10 10 CFU/day B. infantis EVC001 (high) in equal allocation for 28 consecutive days beginning on day 8. Stool samples were collected on study days 7, 10, 14, 21, 28, 35, 42, and 63. Fecal B. infantis levels were significantly higher in all supplement groups compared with placebo on day 28 and day 63. On day 28, fecal B. infantis levels were significantly higher in infants who received any (low, medium, and high) dose compared with baseline. The abundance of fecal Bifidobacteriaceae significantly increased nearly 2-fold in response to B. infantis EVC001 supplementation. No matter the dose, probiotic supplementation with B. infantis in 2- to 4-month-old exclusively breastfed infants resulted in colonization until at least 1 month post-supplementation. IMPORTANCE This study found that supplementing exclusively breastfed infants with a probiotic, Bifidobacterium infantis EVC001, between 2 and 4 months of age can successfully restore beneficial bacteria in their gut, even after the newborn period. Although previous research showed this effect in newborns, this is the first study to demonstrate that older infants, whose gut microbiomes are typically more stable, can still benefit. The probiotic was effective at all tested doses, with higher levels of B. infantis and overall Bifidobacteriaceae in infants' stool during and even 1 month after supplementation. This study demonstrates that B. infantis can take hold in the gut and potentially improve gut health in older breastfed babies, offering a promising approach to support infant health in settings where beneficial gut bacteria are often missing. CLINICAL TRIALS This study was registered at clinicaltrials.gov as NCT03476447 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health and Environmental Sciences Institute, Washington, DC, USA.
- Department of Nutrition, University of Nevada, Reno, Nevada, USA.
- Reno School of Medicine, University of Nevada, Reno, Nevada, USA.
- Department of Nutrition, University of California Davis, Davis, California, USA.
- PumpKin Baby Inc., Princeton, New Jersey, USA.
- InnerPlant Inc., Davis, California, USA.
ORCID-Profile: Steven A Frese, Jennifer T Smilowitz
Zitieren
APA
O'Brien, C. E., Frese, S. A., Cernioglo, K., Damian-Medina, K., Mitchell, R. D., Casaburi, G., Melnyk, R. A., Henrick, B. M., & Smilowitz, J. T. (2026). Randomized, placebo-controlled trial reveals the impact of dose and timing of Bifidobacterium infantis probiotic supplementation on breastfed infants’ gut microbiome. mSphere. https://doi.org/10.1128/msphere.00518-25
Vancouver
O'Brien CE, Frese SA, Cernioglo K, Damian-Medina K, Mitchell RD, Casaburi G, et al. Randomized, placebo-controlled trial reveals the impact of dose and timing of Bifidobacterium infantis probiotic supplementation on breastfed infants’ gut microbiome. mSphere. 2026. doi:10.1128/msphere.00518-25
BibTeX
@article{OBrien2026,
author = {O'Brien, Claire E and Frese, Steven A and Cernioglo, Karina and Damian-Medina, Karla and Mitchell, Ryan D and Casaburi, Giorgio and Melnyk, Ryan A and Henrick, Bethany M and Smilowitz, Jennifer T},
title = {Randomized, placebo-controlled trial reveals the impact of dose and timing of Bifidobacterium infantis probiotic supplementation on breastfed infants’ gut microbiome},
journal = {mSphere},
year = {2026},
doi = {10.1128/msphere.00518-25}
}
EUVIMED